Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a ke...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/ https://www.ncbi.nlm.nih.gov/pubmed/25075121 http://dx.doi.org/10.1136/bjophthalmol-2014-305041 |
_version_ | 1782359646255710208 |
---|---|
author | Gerding, Heinrich Monés, Jordi Tadayoni, Ramin Boscia, Francesco Pearce, Ian Priglinger, Siegfried |
author_facet | Gerding, Heinrich Monés, Jordi Tadayoni, Ramin Boscia, Francesco Pearce, Ian Priglinger, Siegfried |
author_sort | Gerding, Heinrich |
collection | PubMed |
description | Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment. |
format | Online Article Text |
id | pubmed-4345884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43458842015-03-18 Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel Gerding, Heinrich Monés, Jordi Tadayoni, Ramin Boscia, Francesco Pearce, Ian Priglinger, Siegfried Br J Ophthalmol Review Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment. BMJ Publishing Group 2015-03 2014-07-29 /pmc/articles/PMC4345884/ /pubmed/25075121 http://dx.doi.org/10.1136/bjophthalmol-2014-305041 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Review Gerding, Heinrich Monés, Jordi Tadayoni, Ramin Boscia, Francesco Pearce, Ian Priglinger, Siegfried Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
title | Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
title_full | Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
title_fullStr | Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
title_full_unstemmed | Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
title_short | Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
title_sort | ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/ https://www.ncbi.nlm.nih.gov/pubmed/25075121 http://dx.doi.org/10.1136/bjophthalmol-2014-305041 |
work_keys_str_mv | AT gerdingheinrich ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel AT monesjordi ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel AT tadayoniramin ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel AT bosciafrancesco ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel AT pearceian ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel AT priglingersiegfried ranibizumabinretinalveinocclusiontreatmentrecommendationsbyanexpertpanel |